Upstate Active Clinical Trials
Study Title:
A Phase-1, Double-blind, Randomized, Placebo-controlled Study to Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge ModelWhat is the purpose of the study? (in Layman's terms, please describe the study)
To test the effectiveness of an oral drug candidate against dengue virus. This virus causes Dengue fever, a problematic disease for much of the developing world and also for deployed military personnel.Upstate Institutional Review Board (IRB) Number:
1846237Study/Protocol ID:
AT-02A-003Study Phase:
1Patient Age Group:
AdultsPrincipal Investigator:
Stephen J ThomasWho is eligible?
Healthy adults ages 18-49What is involved if I participate?
- How long is the study?
4 months. Visits are frequent during the first two weeks. - Is transportation provided or reimbursed?
Yes - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
Blood draws for labs, physical assessment, ECG, challenge with dengue virus
Where will the study take place?
Global Health Research Unit, Upstate Community campus (4900 Broad Road, Syracuse), POB-North Suite 4UOther Information:
Students are especially welcome, but any healthy adult with a flexible schedule and a desire to advance the science of treating dengue fever is welcome to make an appointment for screening.Who can I contact for more information?
Name: Michelle D Klick
Phone: 315-464-5729
Email: klickm@upstate.edu